Oral gabapentin vs placeboAcquiring ability to walk · adults with SMA types II and III1 finding from 1 reviewDrug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes onlyno estimate extracted1 study · 73 participantsLow
Oral gabapentin vs placeboChange in quality of life · adults with SMA types II and III1 finding from 1 reviewDrug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes onlyno estimate extracted1 study · 67 participantsLow
Oral gabapentin vs placeboChange in pulmonary function · adults with SMA types II and III1 finding from 1 reviewDrug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes onlyno estimate extracted1 study · 65 participantsLow
Oral gabapentin vs placeboTime from beginning of treatment until death or full‐time ventilation · adults with SMA types II and III1 finding from 1 reviewDrug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes onlyno estimate extracted1 study · 84 participantsModerate
Oral gabapentin vs placeboAdverse events related to treatment · adults with SMA types II and III1 finding from 1 reviewDrug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes onlyno estimate extracted1 study · 65 participantsLow
Oral gabapentin vs placeboChange in disability score · adults with SMA types II and III1 finding from 1 reviewDrug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes onlyno estimate extracted1 study · 66 participantsLow
Oral gabapentin vs placeboMuscle strength · adults with SMA types II and III1 finding from 1 reviewDrug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes onlyno estimate extracted1 study · 50 participantsLow